// App-Quantinova.ai

: Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

Researchers

Presenter

  • S Verma

Principal Investigators

  • D C Mazer

  • D L Bhatt

  • S R Raj

  • A T Yan

  • A Verma

  • E Ferrannini

  • G Simons

  • J Lee

  • B Zinman

Medical Centers

  • St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada

  • St Michael's Hospital, Department of Anesthesia, University of Toronto, Toronto, Canada

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • Vanderbilt University, Division of Clinical Pharmacology, Nashville, United States of America

  • St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada

  • University of Milan, School of Medicine, Milan, Italy

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Lunenfeld-Tanenbaum Research Institute of Sinai Health System, University of Toronto, Toronto, Ontario, Canada

Locations

  • Canada

  • Italy

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • The Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved